Health Canada. “Approval of SATIVEX® with Conditions Fact Sheet.” Last accessed 16 December 2005. Available at xxxx://xxx.xx-xx.xx.xx/dhp-mps/prodpharma/notices-avis/conditions/sativex_factsheet_e.html. London, UK; Princeton, NJ, USA; Tokyo, Japan; 14 February 2007: GW Pharmaceuticals plc (AIM: GWP) and Otsuka Pharmaceutical Co., Ltd. today announce that they have entered into a major long term strategic cannabinoid alliance. The relationship has commenced with the signing of an exclusive license and development agreement to develop and market Sativex®, GW’s lead product, in the United States. The companies are also in detailed discussions with a view to entering into a cannabinoid research collaboration in the field of Central Nervous System (CNS) disorders and cancer treatment in order to research, develop and commercialize a range of other early stage cannabinoid product opportunities. The Otsuka Pharmaceutical Group has placed significant emphasis on the research of CNS disorders for the past 27 years. Otsuka’s lead product in the field of CNS ranks among the top seven product launches in industry history and the No. 1 product launch since 2002. Worldwide revenues from this product increased from $1.3bn in 2005 to over $1.9bn in 2006. The Group is privately owned, comprises 87 companies and employs approximately 27,000 people in 17 countries and regions worldwide. It earned revenues of $6.8 billion in fiscal 2005, ranking it the 26th largest pharmaceutical company in the world(2). Otsuka is continuing to expand its CNS specialty sales force presence in the US.
Health Canada. As of April 30, 2018, all Material Contracts and written correspondence or written notice received from Health Canada in relation to any Authorization from Health Canada have been provided to the Buyer or made available in the Company Data Room.
Health Canada. All written correspondence or written notice received from Health Canada in relation to the Required Licenses have been made available to the Purchaser.
Health Canada. All Material Contracts in relation to the licences and permits issued by Health Canada have been provided to or made available to the Purchaser and its representatives.
Health Canada. First Nations health care in transition: the Alberta story - finding new ways to improve client health. (Online) 2005. Available: xxxx://xxx.xx-xx.xx.xx/fniah-spnia/services/ ehealth-esante/alta_clients-eng.php (Accessed 26 April 2005).
Health Canada. Alberta First Nations telehealth program. (Online) 2005. Available: xxxx://xxx.xx-xx.xx.xx/fniah-spnia/ services/ehealth-esante/tele/ab-eng.php (Accessed 27 April 2005).
Health Canada. As of January 21, 2019, all written correspondence or written notice received from Health Canada in relation to the Required Licenses have been made available to Tilray.
Health Canada. All of the Redecan Licences and all other material licenses, and all material correspondence or material written notices received from Health Canada in relation to any Acquired Entity have been provided to or made available to the Purchaser. Except as set out in Section 4.19 of the Sellers’ Disclosure Letter, no consent, waiver or approval is required to be obtained in order to maintain the Redecan Licences in full force and effect immediately upon the consummation of the Transactions.
Health Canada. As of the date hereof, all Material Contracts of ICC Group and written correspondence or written notice received from Health Canada in relation to the ICC Licenses have been provided to or made available to Aurora and its Representatives.
Health Canada. All of the Newstrike Licences and all material correspondence or material written notices received from Health Canada in relation to Company have been provided to or made available to the Purchaser.
